MWNA
CLLS

Marshall Wace North America’s Cellectis CLLS Stock Holding History

Marshall Wace North America’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-32,209
Closed -$574K – 1241
2020
Q2 		$574K Buy
+32,209
New +$490K ﹤0.01% 898

Other funds holding CLLS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Marshall Wace North America's CLLS Position: Q3 2020 in Review

Marshall Wace North America sold out of Cellectis (CLLS) in Q3 2020, closing a stake of 32,209 shares — an estimated $574K sold.

Marshall Wace North America first reported a position in CLLS in Q2 2020 and held it in 1 quarter. The position peaked at $574K in Q2 2020. 74 funds tracked by Wall St. Rank hold CLLS as of Q3 2020.

  • Marshall Wace North America reported no remaining Cellectis position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 32,209 Cellectis shares in Q3 2020, an estimated $574K.
  • Marshall Wace North America first reported a position in Cellectis in Q2 2020 and held it in 1 quarter.
  • Marshall Wace North America's Cellectis position peaked at $574K in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Cellectis as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.